| Document |
Document Title |
|
WO/1992/013872A1 |
Compounds of general formula (I) in the form of a 22R and 22S epimer, wherein X1 and X2 are the same or different and each represents a hydrogen atom or a fluorine atom, provided that X1 and X2 are not simultaneously a hydrogen atom, pro...
|
|
WO/1992/011277A1 |
Compounds have general formula (I), in which X stands for an oxygen atom or for the hydroxyimino grouping >N$m(k)OH; R?1¿ stands for a hydrogen atom or for a methyl group; G stands for a hydrogen, halogen atom, a C¿1?-C¿4? alkyl resid...
|
|
WO/1992/011278A1 |
New compounds having the general formula (I), as well as their pharmacologically acceptable addition salts with acids, are disclosed. In the formula (I), either (Ia) R?11¿ stands for a hydrogen atom in the $g(b) position, whereas R?12¿...
|
|
WO/1992/011279A1 |
A new type of D-homo-(16-en)-11$g(b)-aryl-4-estrenes having general formula (I), as well as their pharmacologically acceptable addition salts with acids are disclosed. In formula (I), X stands for an oxygen atom, the hydroxyimino groupin...
|
|
WO/1992/008730A1 |
A novel method is provided for crystallizing organic and particularly steroidal substances. In particular, a crystallization method is provided whereby a predeterminable and homogenous particle size class can be obtained non-mechanically...
|
|
WO/1992/001706A1 |
The invention relates to the field of organic chemistry and more particularly to therapeutical chemistry. It relates in particular to 6-methyl 19-nor pregna 4,6-diene 20-one having general formula (I) wherein R1 is hydrogen and R2 is a r...
|
|
WO/1991/019731A1 |
Novel angiostatic $g(D)?4,9(11)�-steroids (I), C�21?-oxygenated steroids (II) and other known steroidal compounds have been found to be useful in treating angiogenesis in mammals who have a need for the same. These steroids are usefu...
|
|
WO/1991/019732A1 |
Invented are 3-acetic acid-steroidal compounds, pharmaceutical compositions containing the compounds, and methods of using these compounds to inhibit steroid 5alpha-reductase including using these compounds to reduce prostate size and to...
|
|
WO/1991/016897A1 |
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-ammobutyric acid/benzodiazepine r...
|
|
WO/1991/014700A2 |
A process for preparing novel corticosteroid intermediates of formula (XXX) are disclosed. The process entails contacting a 9alpha-hydroxysteroid of formula (XX) with (A) in step (a) an anhydride, an organic acid and an acid reagent havi...
|
|
WO/1991/010743A1 |
The invention is directed to the control of cellular autophagy, cellular agglutination and the immobilization of motile cells. Such control is useful in, for example, the treatment of cancer, contraception, termination of pregnancy, remo...
|
|
WO/1991/005754A2 |
Derivatives of long-chain fatty alcohols, and methods of obtaining them, are provided, as well as pharmaceutical compositions containing derivatives and their uses, in particular in treating or preventing neuro-degenerative illnesses, co...
|
|
WO/1991/004265A1 |
A process is described for producing progesterone derivatives of general formula (I), in which .... is a single or double bond, X is a hydrogen or fluorine atom or a methyl group and V is a methylene, ethylene, ethylidene or vinylidene g...
|
|
WO/1991/003219A1 |
A matrix for containing drugs for transdermal delivery systems is disclosed. The matrix, formed of a skin-adhesive acrylate copolymer, attains high rates of drug delivery without the addition of drug delivery rate enhancers. In preferred...
|
|
WO/1991/000732A1 |
Methods for treating sex steroid-dependent diseases by inhibiting sex steroid activity include administration of novel compounds which include an androgenic nucleus substituted at a ring carbon with at least one substituent specified her...
|
|
WO/1990/015067A2 |
The invention relates to the field of organic chemistry and to steroid chemistry in particular. Its particular subject are novel 6-methyl estra 4,6-dienes of general formula (I) in which A is hydrogen or a lower oxoalkyl radical and B is...
|
|
WO/1990/013558A1 |
Method for preparing 21-brom-4-pregnen-3,20-dione derivatives of general formula (I), in which R¿1? is a hydrogen atom, a hydroxy group or an alkanoyl group with 1 to 6 carbon atoms, R¿2? is a hydrogen atom or a methyl group, or in whi...
|
|
WO/1990/012027A1 |
The invention, which relates to the domain of chemistry and in particular therapeutic chemistry, essentially has as its subject matter b-methyl 19-nor pregna 4,6-dienes 17alpha, and if necessary, 21-alkylates of general formula (I) in wh...
|
|
WO/1990/011290A1 |
The invention concerns a method for the preparation of 3-desoxy-4-ene steroids of the general formula I in which R¿1?, R¿2? and R¿3? are a hydrogen atom or a methyl group, R¿4? is a lower alkyl group, a phenyl group or a free, esteri...
|
|
WO/1990/009795A1 |
This invention relates to an antiasthmatic agent having an excellent antiasthmatic activity and high safety, containing deprodone propionate of formula (I), as an active ingredient.
|
|
WO/1990/009394A2 |
The process of the present invention is a process for the preparation of an 11-oxygenated steroid of formula (II) which comprises (1) contacting a 9alpha-halo steroid of formula (I) with a metal selected from the group consisting of tin ...
|
|
WO/1990/000174A1 |
The invention concerns 13-Alkyl-11beta-phenylgonanes of general formula (I), wherein Z, R1, R2, R3 and R4 have the meaning given, a process for their preparation, pharmaceutical preparations containing these compounds, and their use for ...
|
|
WO/1989/012448A1 |
An 11beta-aryl-19-norprogesterone steroid of formula (I): wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5, wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl, ...
|
|
WO/1989/011282A1 |
Invented are substituted acrylate analogues of steroidal synthetic compounds, pharmaceutical compositions containing the compounds, and methods of using these compounds to inhibit steroid 5-alpha-reductase including using these compounds...
|
|
WO/1989/010963A1 |
Genetically engineered host cells containing new expression cassettes are provided which are able to carry out biochemical oxidations of steroids. In particular the oxidation is carried out with cells into which DNA has been introduced w...
|
|
WO/1989/009781A1 |
New 9alpha-hydroxy-17-methylene steroids are prepared by the introduction of a substituted 17-methylene group in 9alpha-hydroxyandrost-4-ene-3,17-dione. The resulting compounds are useful starting compounds in the synthesis of corticoste...
|
|
WO/1989/002272A1 |
A method of using 3-hydroxylated-5-reduced steroids and certain novel derivatives which act at a newly identified site on the GBR complex, to modulate brain excitability in a manner which will alleviate stress, anxiety, and seizure activ...
|
|
WO/1989/001483A1 |
The invention involves a two-step chemical transformation of a steroidal 17-cyanohydrin of formula (II) to a 17alpha-hydroxy-21-halo-20-keto steroid of formula (IV) intermediate which can readily be converted to pharmaceutically useful c...
|
|
WO/1989/001482A1 |
The present invention involves improved processes for the dehalogenation of 9alpha-halosteroids (I), to produce the corresponding 11beta-hydroxy steroids (II), which are known to be useful as pharmaceutical, where the improvements compri...
|
|
WO/1989/000558A1 |
Amine salts of alkane-1,n-dicarboxylic acid mono-(2-sulfato-ethyl)amides of the formula (I): HOC(O)-(CH2)n-C(O)-N(R1)-CH2CH2SO3 - + HN(R2)3, wherein R1 is selected from the group consisting of hydrogen, C1-C8 alkyl and phenyl, R2 is C1-C...
|
|
WO/1988/007986A2 |
Compound useful particularly for the treatment by targetted radiotherapy or imaging of cancer, characterized in that the compound is comprised of a molecule susceptible of fixing itself or passing close to the DNA of the target cells, sa...
|
|
WO/1988/005782A1 |
Compounds of formula (I), wherein X represents =O or H(alpha)OH(beta), and Y represents H(alpha) or OH(alpha), which are prepared by bringing 4-pregnene-3,20-dione into contact with microorganisms belonging to the genus Acremonium. These...
|
|
WO/1988/003534A1 |
17beta-Cyano-17alpha-hydroxy steroids (I) are transformed to 17alpha-halo silyl ethers (II) which are intermediates useful in the production of progesterones (V), 17-hydroxyprogesterones (VI), corticoids (VII) and 21-halo corticoids (III...
|
|
WO/1988/002753A2 |
New 9-alpha-hydroxy steroids are prepared by the introduction of substituents on the D-ring of 9-alpha-hydroxy-androst-4-ene-3,17-dione. The resulting compounds are useful intermediates in the synthesis of corticosteroids.
|
|
WO/1987/007895A1 |
Androstane-type aminoesters (IV) and cortical aminoesters (VIII), more particularly 17-aminoesters (I), 11,17-diaminoesters (II), 3,17-diaminoesters (III), 21-aminoesters (V), 11-aminoesters (VI), and 3-aminoesters (VII) which are useful...
|
|
WO/1987/005028A1 |
Compounds of formula (I), wherein one X is COOR, CH2COOR, CH(COOR)2, CONHR, CH2CONHR, or CN; remaining X's are H, F, CH3, OH, COOR, CH2COOR, CH(COOR)2, CONHR, CH2CONHR, or CN; Y is (i1), (i2), (i3), (i4), or (i5); R is H, alkyl of 1-5 ca...
|
|
WO/1987/002672A1 |
Novel tetrahydro steroids which are useful in inhibiting angiogenesis and have the following structure: A compound of formula (I), wherein R15 is = O or -OH; wherein R23 with R10 forms a cyclic phosphate of formula (II) or wherein R23 is...
|
|
WO/1987/001706A2 |
Disclosed are DELTA9(11)-steroids (VI) and amino substituted steroids of formula (XI), which contain an amino group attached to the terminal carbon atom of the C17-side chain, more particularly amino steroids (Ia and Ib), aromatic steroi...
|
|
WO/1987/000175A1 |
9alpha, 11beta and 11beta-susbstituted estranes which exhibit elevated estrogenic and postcoital contraceptive activities. A process for their manufacture and their use in pharmaceuticals is also disclosed.
|
|
WO/1986/000907A1 |
A process for the manufacture of 6alpha-methyl steroids having general formula (I) in which X is a hydroxy group and Y a hydrogen atom, or X and Y are together a carbon-carbon bond and R1 is a cyano group, an acetyl group or an alkanoylo...
|
|
WO/1985/001504A1 |
The particular object of the present invention is a process which comprises subjecting 3-alkoxy 19-nor pregna 3, 5, 17 (20)-triene to the action of a formylation reactant to obtain the corresponding 6-formylated derivative, to reduce it ...
|
|
WO/1985/000609A1 |
Novel steroids having formula (I), wherein, R1 is selected from the group consisting of methyl, ethyl, and propyl; R2 is selected from the group consisting of H and methyl; R3 is selected from the group consisting of OXO and H(OR5);$(12,...
|
|
WO/1983/003099A1 |
The invention relates to products having the general formula I, wherein R1 is thienyl or phenyl optionally substituted, furyl, cycloalkyl, naphtyl, phenyl-phenyl, alkyl or alkenyl; R2 is methyl or ethyl; R3 is H, OH, alkyl, alkenyl, opti...
|
|
JP2024033000A |
[Problem] To provide a method for treating a disease. [Solution] Formula (I) (In the formula, R3a,R5,R6a,R6b,R17,R21a,R21b,Rm,Rn,R16a,R16b,R7a,R7b,R12a,R1
2b,R11a,R11b,R2a,R2b,R19,R4a, and R4bprovided herein is a deuterated compound of (...
|
|
JP7443358B2 |
Neuroactive steroid anaesthetic agents, methods for their preparation and compositions comprising the same are disclosed. Also provided are scaled up and/or GMP methods for preparing neuroactive steroids, such as alfaxalone, alfadolone a...
|
|
JP7438956B2 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...
|
|
JP2024505736A |
The present invention provides crystals of a compound of formula I which is a 3-hydroxy-5-pregnan-20-one derivative and a method for producing the same. Specifically, the present invention provides new crystal forms A to C of a compound ...
|
|
JP7382326B2 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
JP2023162307A |
To provide lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, and methods of producing such lipid prodrugs and pharmaceutical compositions thereof to a patient in need thereof to treat a disease, a disorder, ...
|
|
JP2023113862A |
To provide compositions and methods for treating CNS disorders.Provided herein are compounds of Formula (II-I) in the figure and pharmaceutically acceptable salts thereof. In Formula (II-I), : t is 1, 2 or 3; n is 0, 1 or 2; R19 is subst...
|
